Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EBITDA (2023 - 2026)

Compass Therapeutics' EBITDA history spans 4 years, with the latest figure at -$18.8 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 12.63% to -$18.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$68.5 million, a 24.71% decrease, with the full-year FY2025 number at -$66.4 million, down 34.99% from a year prior.
  • EBITDA hit -$18.8 million in Q1 2026 for Compass Therapeutics, down from -$15.7 million in the prior quarter.
  • Over the last five years, EBITDA for CMPX hit a ceiling of -$7.7 million in Q1 2023 and a floor of -$19.9 million in Q2 2025.
  • Historically, EBITDA has averaged -$13.6 million across 4 years, with a median of -$13.1 million in 2024.
  • Biggest five-year swings in EBITDA: fell 0.17% in 2024 and later crashed 52.58% in 2025.
  • Tracing CMPX's EBITDA over 4 years: stood at -$12.9 million in 2023, then fell by 18.23% to -$15.3 million in 2024, then decreased by 2.62% to -$15.7 million in 2025, then dropped by 19.39% to -$18.8 million in 2026.
  • Business Quant data shows EBITDA for CMPX at -$18.8 million in Q1 2026, -$15.7 million in Q4 2025, and -$14.2 million in Q3 2025.